Aurinia Pharmaceuticals Inc. Stock Toronto S.E.
Equities
AUP
CA05156V1022
Biotechnology & Medical Research
Sales 2024 * | 223M 305M | Sales 2025 * | 288M 393M | Capitalization | 704M 962M |
---|---|---|---|---|---|
Net income 2024 * | -6M -8.19M | Net income 2025 * | 58M 79.19M | EV / Sales 2024 * | 1.61 x |
Net cash position 2024 * | 344M 470M | Net cash position 2025 * | 390M 533M | EV / Sales 2025 * | 1.09 x |
P/E ratio 2024 * |
-88.5
x | P/E ratio 2025 * |
12.3
x | Employees | 300 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.55% |
Latest transcript on Aurinia Pharmaceuticals Inc.
Managers | Title | Age | Since |
---|---|---|---|
Michael Martin
FOU | Founder | 52 | 93-06-15 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 19-04-28 |
Robert Foster
FOU | Founder | 65 | 93-06-15 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Foster
FOU | Founder | 65 | 93-06-15 |
R. MacKay-Dunn
BRD | Director/Board Member | 73 | 19-06-25 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 19-04-28 |
1st Jan change | Capi. | |
---|---|---|
-2.26% | 104B | |
+1.41% | 97.42B | |
+0.79% | 22.2B | |
-17.84% | 21.23B | |
-11.11% | 18.33B | |
-42.83% | 16.35B | |
-17.63% | 15.06B | |
+4.55% | 13.98B | |
+32.11% | 11.66B |